The priorities/needs of the pharmaceutical industry in drug delivery to the brain

International Congress Series

Volumn 1277, Issue , 2005, Pages 32-46

  Lemaire, Michel ^a   Desrayaud, Sandrine ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Blood brain barrier; Blood cerebrospinal fluid barrier; Central nervous system; Drug delivery; Transporter

Indexed keywords

EID: 33646453258     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2005.02.010     Document Type: Article

References (61)

1. Strazielle N., Khuth S.T., and Ghersi-Egea J.F. Detoxification systems, passive and active transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv. Drug Deliv. Rev. 56 (2004) 1717-1740
2. Pardridge W.M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv. Drug Deliv. Rev. 15 (1995) 5-36
3. Jolliet-Riant P., and Tillement J.P. Drug transfer across the blood-brain barrier and improvements of brain delivery. Fundam. Clin. Pharmacol. 13 (1999) 16-26
4. Kusuhara H., and Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (part 1). Drug Discov. Today 6 3 (2001) 150-156
5. Foster K.A., and Roberts M.S. Experimental methods for studying drug uptake in the head and brain. Current Drug Metabolism 1 (2000) 333-356
6. Feng M.R. Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Current Drug Metabolism 3 (2002) 647-657
7. Mertsch K., and Maas J. Blood-brain barrier penetration and drug development from an industrial point of view. Curr. Med. Chem. Central Nervous System Agents 2 (2002) 187-201
8. Scherrmann J.M. Drug delivery to brain via the blood-brain barrier. Vascular Pharmacol. 38 (2002) 349-354
9. Siegal T., and Zylber-Katz E. Strategies for increasing drug delivery to the brain. Clin. Pharmacokinet. 41 3 (2002) 171-186
10. Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 8 20 (2003) 927-973
11. Lobell M., Molnar L., and Keseru G.M. Recent advances in the prediction of blood-brain partitioning from molecular structure. J. Pharm. Sci. 92 2 (2003) 360-370
12. Liu X., et al. Development of a computational approach to predict blood-brain barrier permeability. Drug Met. Dispos. 32 1 (2004) 132-139
13. Platts J.A., et al. Correlation and prediction of a large blood-brain distribution data set-an LFER study. Eur. J. Med. Chem. 36 9 (2001) 719-730
14. Lombardo F., Blake J.F., and Curatolo W.J. Computation of brain-blood partitioning of organic solutes via free energy calculations. J. Med. Chem. 39 (1996) 4750-4755
15. Kelder J., et al. Polar molecule surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 16 10 (1999) 1514-1519
16. Pardridge W.M. Isolated brain capillaries: an in vitro model of blood-brain barrier research. In: Pardridge W.M. (Ed). Introduction to the Blood-Brain Barrier: Methodology, Biology and Pathology (1998), University Press, Cambridge 49-61
17. Audus K.L., and Borchardt R.T. Characterisation of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm. Res. 3 (1986) 81-87
18. Franke H., Galla H.J., and Beuckmann C.T. Primary cultures of brain microvessellendothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Protoc. 5 3 (2000) 248-256
19. Bauer B., Miller D.S., and Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm. Res. 20 8 (2003) 1170-1176
20. Dehouck M.P., et al. Drug transport to the brain: comparison between in vitro and in vivo models of the blood-brain barrier. Eur. J. Pharm. Sci. 3 (1995) 357-365
21. Gaillard P.J., et al. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain endothelial cells and astrocytes. Eur. J. Pharm. Sci. 12 3 (2001) 215-222
22. Terasaki T., et al. New approaches to in vitro models of blood-brain barrier drug transport. DDT 8 (2003) 944-954
23. Megard I., et al. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res. 927 2 (2002) 153-167
24. Strazielle N., and Preston J.E. Transport across the choroid plexuses in vivo and in vitro. In: Nag S. (Ed). The blood-brain barrier (2003), Humana Press, Totowa 291-304
25. Oldendorf W.H. Measurements of brain uptake of radiolabelled substances using a tritiated water internal standard. Brain Res. 24 (1970) 372-376
26. Dagenais C., et al. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein deficient mice. J. Cereb. Blood Flow Metab. 20 2 (2000) 381-386
27. Takasato Y., Rapoport S.I., and Smith Q.R. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247 (1984) H484-H493
28. Zlokovic B.V., et al. Measurement of solute transport across the blood-brain barrier in the perfused guinea pig brain: method and application to N-methyl-α-aminoisobutyric acid. J. Neurochem. 46 (1986) 1444-1451
29. Triguero D., Buciak J., and Pardridge W.M. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54 (1990) 1882-1888
30. Kakee A., Terasaki T., and Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277 (1996) 1550-1559
31. Zhang Y., and Pardridge W.M. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J. Neuroimmunol. 114 (2001) 168-172
32. Schinkel A.H., et al. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Invest 96 4 (1995) 1698-1705
33. Desrayaud S., et al. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. 61 2 (1997) 153-163
34. De Lange E.M., de Boer A.G., and Breimer D.D. Monitoring in vivo blood-brain barrier transport: cerebrospinal fluid sampling, the unit impulse response method and, with special reference, intracerebral microdialysis. STP Pharma. Sciences 7 1 (1997) 17-27
35. De Lange E.C.M., and Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting. Clin. Pharmacokinet. 41 10 (2002) 691-703
36. Shen D.D., Artru A.A., and Adkison K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv. Drug Deliv. Rev. 56 (2004) 1825-1857
37. Anthonypillai C., et al. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J. Pharmacol. Exp. Ther. 308 (2004) 912-920
38. Wallace M.C., Teasdale G.M., and McCullough J. Autoradiographic analysis of 3H-MK-801 (dizocilpine) in vivo uptake and in vitro binding after focal cerebral ischemia in the rat. J. Neurosurg. 76 (1992) 127-133
39. Fischman A.J., Alpert N.M., and Rubin R.H. Pharmacokinetic imaging. A noninvasive method for determinig drug distribution and action. Clin. Pharmacokinet. 41 8 (2002) 581-602
40. Hendrikse N.H., et al. P-glycoprotein at the blood-brain barrier and analysis of drug transport with positron-emission tomography. J. Clin. Pharmacol. 41 (2001) 48S-54S
41. Sawchuk R.J., and Elmquist W.F. Microdialysis in the study of drug transporters in the CNS. Adv. Drug Deliv. Rev. 45 (2000) 295-307
42. Deguchi Y. Application of in vivo brain microdialysis to the study of blood-brain barrier transport of drugs. Drug Metab. Pharmacokin. 17 5 (2002) 395-407
43. Pardridge W.M. Invasive brain drug delivery. In: Pardridge W.M. (Ed). Brain drug targeting (2001), University Press, Cambridge 13-35
44. Wang P.P., Frazier J., and Brem H. Local drug delivery to the brain. Adv. Drug Deliv. Rev. 54 (2002) 987-1013
45. Thorne R.G., and Frey W.H. Delivery of neurotrophic factors to the central nervous system. Clin. Pharmacokinet. 40 12 (2001) 907-946
46. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11 1 (2000) 1-18
47. Banks W.A., During M.J., and Niehoff M.L. Brain uptake of the glucagon-like peptide-1 antagonist Exendin (9-39) after intranasal administration. J. Pharmacol. Exp. Ther. 309 (2004) 469-475
48. Born J., et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5 6 (2002) 514-516
49. Zylber-Katz E., et al. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma. Clin. Pharmacol. Ther. 67 6 (2000) 631-641
50. Borlongan C.V., and Emerich D.F. Facilitation of drug entry into the CNS via transient permeation of blood-brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, cereport. Brain Res. Bull. 60 (2003) 297-306
51. Bodor N. Drug targeting and retrometabolic drug design approaches. Adv. Drug Deliv. Rev. 14 (1994) 157-166
52. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 (2001) 65-81
53. Lockman P.R., et al. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20 5 (2003) 705-713
54. De Boer A.G., van der Sandt I.C.J., and Gaillard P.J. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 629-656
55. Smith Q.R. Drug delivery to brain and the role carrier-mediated transport. In: Drewes L.R., and Betz A.L. (Eds). Frontiers in cerebral vascular biology: transport and its regulation metabolism and toxicology (1993), Plenum Press, New York 83-93
56. Bickel U., Yoshikawa T., and Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug. Deliv. Rev. 46 (2001) 247-279
57. Huwyler J., Wu D., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U.S.A. 93 24 (1996) 14164-14169
58. Tamai I., et al. Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther. 280 (1997) 410-415
59. Rousselle C., et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 296 (2001) 124-131
60. Taylor E.M. The impact of efflux transporters in the brain on the development of drugs in CNS disorders. Clin. Pharmacokinet. 41 2 (2001) 81-92
61. Pardridge W.M. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. Curr. Opin. Drug Discov. Dev. 6 (2003) 683-691